Restricts certain substances from being used in menstrual products.
S01548 amends New York’s General Business Law to restrict certain chemicals in menstrual products sold or distributed in the state. It defines menstrual products broadly to include tampons, pads, menstrual cups, and similar products, and it defines “restricted substance” to include a list of chemicals such as lead, mercury, formaldehyde, triclosan, toluene, talc, certain phthalates, parabens, and PFAS, as well as any other unsafe chemical identified by the commissioner of health.
The bill prohibits menstrual products from containing any restricted substance that is intentionally added at any level as of the effective date. It also requires the Department of Health, in consultation with the Department of Environmental Conservation, to establish regulatory thresholds for any restricted substance that may be present at unavoidable levels, using the lowest feasible level, no later than one year after the law takes effect. Those thresholds must be reviewed every five years and may be lowered over time. The act takes effect 12 months after becoming law, with immediate authorization for any needed rulemaking.
The bill’s impact is to create a statewide product-safety standard for menstrual products sold at retail or wholesale, used personally or professionally, or distributed for promotional purposes. It expands state oversight of consumer goods by directing health and environmental agencies to set and periodically revisit contamination limits, and it may require manufacturers, distributors, and retailers to reformulate products, change sourcing, or verify compliance with chemical restrictions.
The general sentiment around the bill appears strongly supportive. It passed the Senate unanimously and the Assembly with overwhelming support, indicating broad bipartisan agreement on reducing exposure to potentially harmful chemicals in menstrual products and improving consumer safety.
There is little evidence of major controversy in the available record, but the main point of policy tension is likely the feasibility of meeting the chemical thresholds and the regulatory burden on manufacturers. The bill leaves key implementation details to the Department of Health and DEC, including what levels are technically achievable and how those limits may be lowered over time, which could be a concern for industry while being viewed as necessary by public health advocates.
This bill amends the General Business Law to prohibit the sale or distribution of menstrual products containing intentionally added restricted substances and to require the Department of Health, with DEC consultation, to set enforceable contamination thresholds for unavoidable trace amounts. It affects manufacturers, wholesalers, retailers, and distributors of menstrual products in New York, and it gives state agencies authority to define and periodically update compliance standards for chemicals such as PFAS, phthalates, parabens, lead, mercury, formaldehyde, and related compounds.
The bill appears to have very strong support. It passed the Senate 59-0 and the Assembly 148-1, suggesting broad agreement that menstrual products should be subject to chemical safety restrictions and that the state should act to reduce exposure to potentially harmful substances.
No committee debate or recorded opposition is provided, so there is no clear evidence of organized controversy in the available materials. The likely areas of concern are implementation and compliance: how the state will determine the lowest feasible threshold, how often standards may be tightened, and whether manufacturers can readily reformulate products without disrupting supply or increasing costs. Public health advocates are likely to support the restrictions, while industry stakeholders may focus on feasibility, testing, and regulatory certainty.